Faslodex Post Marketing Surveillance

AstraZeneca42 enrolled

Overview

This PMS aims to assess the efficacy, the safety and tolerability profile of Faslodex in everyday practice. Secondary objective of this PMS is to identify the frequency of serious adverse events or any unknown adverse events of Faslodex.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal women * Patients who have failed 2 or more prior hormone therapies (The prior hormone therapies should contain both antiestrogen and non-steroidal Aromatase inhibitor) * Patients who were intolerant to prior hormone therapy and have no endocrine therapeutic options (The prior hormone therapies should contain both antiestrogen and non-steroidal Aromatase inhibitor) Exclusion Criteria: * The patients who received Faslodex treatment before

Locations (7)

Research Site

Cheonan, South Korea

Research Site

Daegu, South Korea

Research Site

Daejeon, South Korea

Research Site

Iksan, South Korea

Outcomes

Primary Outcomes

Adverse events are confirmed by investigator through asking to patients or patients' voluntary reporting.

Time frame: 5 years

Efficacy of Faslodex is assessed by proper method among CT scan, MRI, Ultrasound, etc. The RECIST criteria for target and non-target lesions will be used to evaluate efficacy.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.